PubRank

Masatoshi Eto

Author PubWeight™ 34.08‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Multicenter phase II trial of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 2010 1.57
2 Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma. Cancer Sci 2011 1.46
3 Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1. Jpn J Clin Oncol 2010 1.18
4 STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. J Clin Oncol 2007 1.06
5 Tip60 promotes prostate cancer cell proliferation by translocation of androgen receptor into the nucleus. Prostate 2010 1.00
6 Current status of pharmacotherapy against metastatic renal cell carcinoma in Japan. Int J Urol 2012 0.98
7 Long-term outcome of hand-assisted laparoscopic radical nephrectomy for localized stage T1/T2 renal-cell carcinoma. J Endourol 2005 0.92
8 IL-17 production by γδ T cells is important for the antitumor effect of Mycobacterium bovis bacillus Calmette-Guérin treatment against bladder cancer. Eur J Immunol 2010 0.91
9 Enhancement of human cancer cell motility and invasiveness by anaphylatoxin C5a via aberrantly expressed C5a receptor (CD88). Clin Cancer Res 2013 0.91
10 Donor CD4 T cells are critical in allogeneic stem cell transplantation against murine solid tumor. Cancer Res 2009 0.90
11 What affects the results of a laparoscopic adrenalectomy for pheochromocytoma? Evaluation with respect to intraoperative blood pressure and state of tumor. J Endourol 2009 0.89
12 Severe bleeding tendency caused by a rare complication of excessive fibrinolysis with disseminated intravascular coagulation in a 51-year-old Japanese man with prostate cancer: a case report. J Med Case Rep 2012 0.86
13 Inositol 1,4,5-trisphosphate (IP3) receptor type1 (IP3R1) modulates the acquisition of cisplatin resistance in bladder cancer cell lines. Oncogene 2005 0.86
14 Sunitinib enhances antitumor effects against chemotherapy-resistant bladder cancer through suppression of ERK1/2 phosphorylation. Int J Oncol 2012 0.85
15 Renal cancer treatment with low levels of mixed chimerism induced by nonmyeloablative regimen using cyclophosphamide in mice. Cancer Res 2005 0.85
16 Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression. Cancer Chemother Pharmacol 2011 0.85
17 Enhanced antitumor effects of an engineered measles virus Edmonston strain expressing the wild-type N, P, L genes on human renal cell carcinoma. Mol Ther 2010 0.85
18 Impact of cold and warm ischemia on postoperative recovery of affected renal function after partial nephrectomy. J Endourol 2011 0.85
19 Influence of immunotherapy with interferon-alpha on regulatory T cells in renal cell carcinoma patients. J Interferon Cytokine Res 2010 0.84
20 Mechanism of synergistic antitumor effect of sorafenib and interferon-α on treatment of renal cell carcinoma. J Urol 2010 0.84
21 Sorafenib with doxorubicin augments cytotoxicity to renal cell cancer through PERK inhibition. Int J Oncol 2010 0.82
22 Oral administration of xanthan gum enhances antitumor activity through Toll-like receptor 4. Int Immunopharmacol 2009 0.82
23 p300 mediates cellular resistance to doxorubicin in bladder cancer. Mol Med Rep 2011 0.82
24 YB-1 suppression induces STAT3 proteolysis and sensitizes renal cancer to interferon-α. Cancer Immunol Immunother 2012 0.82
25 Impacts of clinicopathologic and operative factors on short-term and long-term survival in renal cell carcinoma with venous tumor thrombus extension: a multi-institutional retrospective study in Japan. BMC Cancer 2013 0.81
26 Clinical characteristics and oncological outcomes of testicular cancer patients registered in 2005 and 2008: the first large-scale study from the Cancer Registration Committee of the Japanese Urological Association. Int J Urol 2014 0.80
27 MRI of retroperitoneal solitary fibrous tumor in the suprarenal region. AJR Am J Roentgenol 2007 0.79
28 A reduction of recipient regulatory T cells by cyclophosphamide contributes to an anti-tumor effect of nonmyeloablative allogeneic stem cell transplantation in mice. Int J Cancer 2011 0.79
29 Identification of potential therapeutic targets in hypertension-associated bladder dysfunction. BJU Int 2009 0.78
30 Dendritic-cell therapy after non-myeloablative stem-cell transplantation for renal-cell carcinoma. Lancet Oncol 2004 0.78
31 The efficacy of laparoscopic radical nephrectomy for renal cell cancer in the elderly: an oncological outcome analysis. Int J Urol 2008 0.78
32 In vivo growth of transitional and renal cell carcinoma cell lines can be suppressed by the adenovirus-mediated expression of a soluble form of vascular endothelial growth factor receptor. Oncol Rep 2006 0.77
33 A case of cortisol producing adrenal adenoma associated with a latent aldosteronoma: usefulness of the ACTH loading test for the detection of covert aldosteronism in overt Cushing syndrome. Intern Med 2012 0.77
34 Comparison of standard and hand-assisted laparoscopic radical nephrectomy for renal cell carcinoma. Fukuoka Igaku Zasshi 2007 0.76
35 Dendritic cell therapy in combination with interferon-alpha for the treatment of metastatic renal cell carcinoma. Int J Urol 2008 0.76
36 A pilot study of the assessment of the quality of life, functional results, and complications in patients with an ileal neobladder for invasive bladder cancer. Int J Urol 2007 0.76
37 A C-type lectin receptor pathway is responsible for the pathogenesis of acute cyclophosphamide-induced cystitis in mice. Microbiol Immunol 2013 0.76
38 Sensitivity of doxorubicin-resistant cells to sorafenib: possible role for inhibition of eukaryotic initiation factor-2alpha phosphorylation. Int J Oncol 2010 0.76
39 Unsuspected pheochromocytoma of the urinary bladder in an 81-year-old woman. Hinyokika Kiyo 2006 0.76
40 Molecular mechanisms regulating urogenital expression of nitric oxide synthase in spontaneously hypertensive rats. Life Sci 2009 0.75
41 IJU this issue. Int J Urol 2015 0.75
42 Oncological outcomes of renal pelvic and ureteral cancer patients registered in 2005: the first large population report from the Cancer Registration Committee of the Japanese Urological Association. Int J Urol 2013 0.75
43 [Recent topics in the treatments of renal cell carcinoma]. Gan To Kagaku Ryoho 2016 0.75
44 Inhibition of Aeromonas sobria serine protease (ASP) by α2-macroglobulin. Biol Chem 2012 0.75
45 Current Status and Future Perspective of Tolerance Induction in Patients with Kidney Transplantation. Fukuoka Igaku Zasshi 2016 0.75
46 Allogeneic cell therapy from immunized donors with tumor antigen peptide enhances the antitumor effect after cyclophosphamide-using non-myeloablative allogeneic hematopoietic cell transplantation. Cancer Sci 2008 0.75
47 IJU this issue. Int J Urol 2014 0.75
48 The tail nick augments Aeromonas sobria serine protease (ASP) activity in plasma through retarding inhibition by α2-macroglobulin. FEBS Lett 2012 0.75
49 Exploring immune therapy for renal cancer. Int J Urol 2011 0.75
50 IJU this issue. Int J Urol 2013 0.75
51 [III. Topics of chemotherapy]. Gan To Kagaku Ryoho 2015 0.75
52 [Current status and prospects of immunotherapy for castration-resistant prostate cancer]. Nihon Rinsho 2014 0.75
53 Diversity in treatment modalities of Stage II/III urothelial cancer in Japan: sub-analysis of the multi-institutional national database of the Japanese Urological Association. Jpn J Clin Oncol 2016 0.75
54 [BCG Immunotherapy Against Non-Muscle Invasive Bladder Cancer: Recent Results, Current Studies and Future Perspectives]. Fukuoka Igaku Zasshi 2016 0.75
55 The change of the split renal function before and after a nephrectomy using Tc-mercaptoacetyltriglycine (MAG3). Fukuoka Igaku Zasshi 2005 0.75
56 Fifth joint meeting of the American Urological Association and the Japanese Urological Association International Affiliate Society Meeting at the 105th Annual Meeting of the American Urological Association. Int J Urol 2010 0.75